Why Has IceCure Medical (NASDAQ:ICCM) Climbed 11.87% in Pre-Market Trade on Tuesday?

Vinay Lochav

10 November 2026 11:43 PM AEDT

Why Has IceCure Medical (NASDAQ:ICCM) Climbed 11.87% in Pre-Market Trade on Tuesday?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

IceCure Medical (NASDAQ:ICCM) was indicated at USD 0.9200 before the open on Tuesday, November 10, 2026, an 11.87% gain on a calculated prior close of USD 0.8224 from Monday, November 9.
Published market data places the Market Capitalisation at USD 2.82 million across 3.43 million shares, and the 52-week band stretches from USD 0.65 to USD 22.50.
Trading is light, with 14,994 shares changing hands on the quote page against a daily average of 154.15 thousand, roughly 9.7% of a usual session, calculated.
Revenue reached USD 3,379,000 in fiscal 2025 and USD 3.95 million over the trailing twelve months, yet published coverage flags no catalyst for November 10.

Drivers of IceCure Medical's Pre-Market Rise (+11.87%)

The indication of USD 0.9200 for Tuesday, November 10, 2026 represents a USD 0.0976 per share gain, calculated from the 11.87% change and a prior close of USD 0.8224. Measured against the 52-week high of USD 22.50, the price is 95.9% lower, while it stands 41.5% above the USD 0.65 floor, both calculated. Applying the indicated price to 3.43 million shares yields roughly USD 3.16 million, calculated, against the USD 2.82 million market capitalisation on the quote page. Searches twice came up empty for releases or filings dated November 9 or 10, 2026, so published coverage names no catalyst. The shares trade at about 0.8 times trailing sales, calculated on USD 3.95 million.

The Reasoning: Background Context and What Usually Moves Small Medtechs

IceCure makes the ProSense cryoablation system, a device that freezes tumours. Earlier published coverage linked a 203% single-day spike to US ProSense uptake that rose 70%. Small MedTech names often jump on regulatory decisions, reimbursement shifts, installation tallies or conference talks, and retail traders can push shares near lows higher. A price under USD 1.00 can prompt a Nasdaq minimum bid notice, and a reverse split is a usual remedy. The 52-week high of USD 22.50 sits far above the current price, which points to an earlier large change in the share count, so older price charts may be adjusted.

Valuation, Trading Depth, the 52-Week Span and Risks

At USD 2.82 million, the Market Value sits below one year of Revenue at USD 3.95 million, though the Business is loss-making and needs outside funding. Trading figures are small: 14,994 shares against 154.15 thousand on average, so a small number of orders can shift the quote, and spreads may be wide. Early quotes for a company with 3.43 million shares can lurch by double digits on minimal funds. The main concerns are share issuance, a bid-price shortfall, regulatory timing and a possible unwinding at the 9:30 a.m. ET open. The figures give no sign that the gain will hold.

Where Things Stand

IceCure Medical (NASDAQ:ICCM) is indicated 11.87% higher pre-market at USD 0.9200 with no identified catalyst. The prior close stood at USD 0.82, the market capitalisation is USD 2.82 million, and the 52-week range runs from USD 0.65 to USD 22.50. Volume of 14,994 shares against 154.15 thousand on average shows a thin quote. Investors should look to the next company release, any capital raise and any Nasdaq notice before reading much into the move, since a jump of this size on 14,994 shares tells little about demand.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.